Identification of Cinobufagin and Resibufogenin as Inhibitors of Enterovirus 71 Infection

doi:10.1007/s40242-014-4133-8

Chemical Research in Chinese Universities ›› 2014, Vol. 30 ›› Issue (6): 953-958.doi: 10.1007/s40242-014-4133-8

• Articles • Previous Articles Next Articles

Identification of Cinobufagin and Resibufogenin as Inhibitors of Enterovirus 71 Infection

CHEN Jiawen¹, XU Lin¹, SUN Shiyang^1,2, ZHANG Huafei^1,2, MA Tonghui³, SU Weiheng^1,2, JIANG Chunlai^1,2

1. National Engineering Laboratory for AIDS Vaccine, Changchun 130012, P. R. China;
2. Key Laboratory for Molecular Enzymology & Engineering, Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, P. R. China;
3. College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, P. R. China

Received:2014-04-14 Revised:2014-08-04 Online:2014-12-01 Published:2014-08-13
Contact: SU Weiheng, JIANG Chunlai E-mail:suweiheng@jlu.edu.cn;jiangcl@jlu.edu.cn
Supported by:
Supported by the Young Researcher's Grant from the Science and Technology Development Program of Jilin Province of China(No.20140520001JH).

Abstract

Abstract:

In this paper, cinobufagin and resibufogenin were found to inhibit enterovirus 71(EV71) infection in vitro in cell viability and plaque reduction assays. The 50% inhibitory concentrations(IC₅₀) of cinobufagin and resibufogenin were (10.94±2.36) and (218±31) nmol/L, respectively, the 50% cytotoxic concentrations(CC₅₀) of them were (1277±223) and (1385±254) nmol/L, respectively, and the anti-EV71 selectivity index(SI₅₀) of cinobufagin was 116.7, which are promisingly developed into drug. Using a VP1 detection assay and a constructed reporter luciferase, we found that cinobufagin and resibufogenin disrupted the synthesis of EV71 protein. However, neither of them inhibited EV71 RNA replication. Our study suggests that cinobufagin and resibufogenin are the promising candidates that should be further investigated for the treatment of EV71 caused disease.

Key words: Enterovirus 71, Coxsackievirus A16, Cinobufagin, Resibufogenin, Chansu

CHEN Jiawen, XU Lin, SUN Shiyang, ZHANG Huafei, MA Tonghui, SU Weiheng, JIANG Chunlai. Identification of Cinobufagin and Resibufogenin as Inhibitors of Enterovirus 71 Infection[J]. Chemical Research in Chinese Universities, 2014, 30(6): 953-958.

References

[1] Pourianfar H. R., Grollo L., J. Microbiol. Immunol. Infect., 2014, DOI: 10.1016/j.jmii.2013.11.011
[2] Yip C. C., Lau S. K., Woo P. C., Emerg. Health Threats J., 2013, 6, 19780
[3] Yi L., Lu J., Kung H. F., Crit. Rev. Microbiol., 2011, 37(4), 313
[4] Liang Z., Mao Q., Gao F., Front Med., 2013, 7(1), 111
[5] Li R., Liu L., Mo Z., N. Engl. J. Med., 2014, 370(9), 829
[6] Zhu F., Xu W., Xia J., N. Engl. J. Med., 2014, 370(9), 818
[7] Zhu F. C., Meng F. Y., Li J. X., Lancet, 2013, 381(9882), 2024
[8] Chen T. C., Liu S. C., Huang P. N., J. Biomed. Sci., 2008, 15(3), 291
[9] Chen T. C., Chang H. Y., Lin P. F., Antimicrob. Agents Chemother., 2009, 53(7), 2740
[10] Zhang X., Song Z., Qin B., Antiviral Res., 2013, 97(3), 264
[11] Zhu Q. C., Wang Y., Liu Y. P., Eur. J. Pharm. Sci., 2011, 44(3), 392
[12] Yang Y., Xiu J., Zhang X., Molecules, 2012, 17(9), 10370
[13] Wang J., Chen X., Wang W., J. Ethnopharmacol., 2013, 147(1), 114
[14] Xu L., Su W. H., Jin J., Viruses, 2014, 6, 2778
[15] Qi J., Tan C. K., Hashimi S. M., Evid. Based. Complement. Alternat. Med., 2014, 2014, 312684-1
[16] Nakano H., Matsunawa M., Yasui A., Biochem. Pharmacol., 2005, 70(10), 1479
[17] Akimova O. A., Bagrov A. Y., Lopina O. D., J. Biol. Chem., 2005, 280(1), 832
[18] Rong X., Ni W., Liu Y., Inflammation, 2014, 37(4), 1050
[19] Li C., Hashimi S. M., Cao S., Evid. Based. Complement. Alternat. Med., 2013, 2013, 849054-1
[20] Chen T., Hu W., He H., Evid. Based. Complement. Alternat. Med., 2013, 2013, 851256-1
[21] Liang X. P., Zhang Z., Hu P., Chem. J. Chinese Universities, 2011, 32(1), 38
[22] Cui X., Inagaki Y., Xu H., Biol. Pharm. Bull., 2010, 33(10), 1728
[23] Li X., Fan P., Jin J., Virol. J., 2013, 10, 250-1
[24] Jin J., Ma H., Xu L., J .Virol. Methods, 2013, 187(2), 362
[25] Jin J., Xu L., Guo S., Chem. Res. Chinese Universities, 2012, 28(1), 91
[26] Nijhuis M., van Maarseveen N., Schuurman R., J. Clin. Microbiol., 2002, 40(10), 3666
[27] Chen T. C., Weng K. F., Chang S. C., J. Antimicrob. Chemother., 2008, 62(6), 1169
[28] Li Z. H., Li C. M., Ling P., J. Infect. Dis., 2008, 197(6), 854
[29] Liu M. L., Lee Y. P., Wang Y. F., J. Gen. Virol., 2005, 86(Pt 12), 3263
[30] Sim A. C., Luhur A., Tan T. M., Virology, 2005, 341(1), 72
[31] Wu Z., Yang F., Zhao R., J. Virol. Methods, 2009, 159(2), 233
[32] Tan E. L., Tan T. M., Tak Kwong Chow V., Mol. Ther., 2007, 15(11), 1931
[33] Ooi M. H., Wong S. C., Mohan A., BMC Infect. Dis., 2009, DOI: 10.118611471-2334-9-3
[34] Chang L. Y., Hsia S. H., Wu C. T., Pediatr. Infect. Dis. J., 2004, 23(4), 327
[35] Ooi M. H., Wong S. C., Podin Y., Clin. Infect. Dis., 2007, 44(5), 646
[36] Wang S. M., Liu C. C., Tseng H. W., Clin. Infect. Dis., 1999, 29(1), 184
[37] Lin Y. W., Lin H. Y., Tsou Y. L., PLoS One, 2012, 7(1), e30507ang X., Molecules, 2012, 17(9), 10370
[13] Wang J., Chen X., Wang W., J Ethnopharmacol, 2013, 147(1), 114
[14] Nakano H., Matsunawa M., Yasui A., Biochem Pharmacol, 2005, 70(10), 1479
[15] Akimova O. A., Bagrov A. Y., Lopina O. D., J Biol Chem, 2005, 280(1), 832
[16] Rong X., Ni W., Liu Y., Inflammation, 2014,
[17] Li C., Hashimi S. M., Cao S., Evid Based Complement Alternat Med, 2013, 2013(849054)
[18] Chen T., Hu W., He H., Evid Based Complement Alternat Med, 2013, 2013(851256)
[19] Cui X., Inagaki Y., Xu H., Biol Pharm Bull, 2010, 33(10), 1728
[20] Li X., Fan P., Jin J., Virol J, 2013, 10(250)
[21] Jin J., Ma H., Xu L., J Virol Methods, 2013, 187(2), 362
[22] Jin J., Xu L., Guo S., CHEM. RES. CHINESE UNIVERSITIES, 2012, 28(1), 91—95
[23] Nijhuis M., van Maarseveen N., Schuurman R., J Clin Microbiol, 2002, 40(10), 3666
[24] Chen T. C., Weng K. F., Chang S. C., J Antimicrob Chemother, 2008, 62(6), 1169
[25] Li Z. H., Li C. M., Ling P., J Infect Dis, 2008, 197(6), 854
[26] Liu M. L., Lee Y. P., Wang Y. F., J Gen Virol, 2005, 86(Pt 12), 3263
[27] Sim A. C., Luhur A., Tan T. M., Virology, 2005, 341(1), 72
[28] Wu Z., Yang F., Zhao R., J Virol Methods, 2009, 159(2), 233
[29] Tan E. L., Tan T. M., Tak Kwong Chow V., Mol Ther, 2007, 15(11), 1931
[30] Ooi M. H., Wong S. C., Mohan A., BMC Infect Dis, 2009, 9(3
[31] Chang L. Y., Hsia S. H., Wu C. T., Pediatr Infect Dis J, 2004, 23(4), 327
[32] Ooi M. H., Wong S. C., Podin Y., Clin Infect Dis, 2007, 44(5), 646
[33] Wang S. M., Liu C. C., Tseng H. W., Clin Infect Dis, 1999, 29(1), 184
[34] Lin Y. W., Lin H. Y., Tsou Y. L., PLoS One, 2012, 7(1), e30507

Identification of Cinobufagin and Resibufogenin as Inhibitors of Enterovirus 71 Infection

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	GUO Jinhua, TAN Bei, YE Qingmei, LIANG Guangping, YI Min, JIANG Renwang. Synthesis and Cytotoxic Activities of Spin-labeled Derivatives of Cinobufagin [J]. Chemical Research in Chinese Universities, 2017, 33(4): 581-586.
[2]	LIANG Guangping, CHUNG Tseyu, GUO Jinhua, ZHANG Rongrong, XÜ Wei, TZEN Jason T. C., JIANG Renwang. Novel Cinobufagin Oxime Ether Derivatives as Potential Na⁺/K⁺-ATPase Inhibitors: Synthesis, Biological Screening and Molecular Docking [J]. Chemical Research in Chinese Universities, 2017, 33(3): 378-383.
[3]	JIN Jun, XU Lin, GUO Shi-jie, SUN Shi-yang, ZHANG Shu, ZHU Chang-lin, KONG Wei, JIANG Chun-lai. Safe and Objective Assay of Enterovirus 71 Neutralizing Antibodies via Pseudovirus [J]. Chemical Research in Chinese Universities, 2012, 28(1): 91-95.
[4]	HAN Tian-jiao, WANG Qing, SONG Feng-rui, LIU Zhong-ying, LIU Zhi-qiang*,.... Intestinal Transport and Biotransformation of Resibufogenin and Cinobufagin in Chan Su via HPLC/APCI-MSn [J]. Chemical Research in Chinese Universities, 2011, 27(3): 380-384.